The role of incretin receptor agonists in the treatment of obesity

The objective of this narrative review was to summarize the available data on approved and emerging incretin-based agents for the treatment of obesity.

The role of incretin receptor agonists in the treatment of obesity - Forst

The objective of this narrative review was to summarize the available data on approved and emerging incretin-based agents for the treatment of obesity.

The development of the glucagon-like peptide-1 receptor agonists for chronic weight management has triggered new inter- est in the incretins and ...

Editorial: Incretin agonists in the treatment of obesity - PMC

Exenatide, the first clinically used GLP-1 receptor agonist, has shown potential therapeutic benefits in metabolic disorders. In the original research article, ...

The role of incretin receptor agonists in the treatment of obesity

Request PDF | The role of incretin receptor agonists in the treatment of obesity | Introdroduction Obesity and its associated metabolic ...

Role of incretins and glucagon receptor agonists in metabolic ...

Thus, these agents significantly improve glycemic control and weight management and mitigate MASLD pathogenesis. Importantly, this study ...

Transforming obesity: The advancement of multi-receptor drugs: Cell

These polyagonists reduce body weight through complementary pharmacology by incorporating the receptors for glucagon and/or the glucose-dependent ...

GLP−1 receptor agonists for the treatment of obesity - Frontiers

Glucagon-like peptide-1 receptor (GLP-1R) agonists are a group of drugs that targets incretin hormone action, and its receptors are widely distributed in nerves ...

Incretin hormone agonists: Current and emerging pharmacotherapy ...

The current incretin hormone agonists approved by the FDA for obesity management include liraglutide, semaglutide, and tirzepatide. Key ...

GLP-1 Agonists: What They Are, How They Work & Side Effects

And they're just one part of your treatment plan if you have Type 2 diabetes or obesity. Your healthcare provider can help you decide if they're right for you.

GLP-1 single, dual, and triple receptor agonists for treating type 2 ...

GLP-1, an incretin hormone, plays a crucial role in glucose metabolism and appetite regulation, influencing insulin secretion, insulin sensitivity, and gastric ...

Incretin-Based Weight Loss Pharmacotherapy: Can Resistance ...

Glucagon-like peptide 1 receptor agonists (GLP-1RA) induce substantial weight loss in randomized trials, effects that may be enhanced in ...

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From ...

As already alluded to, infusions of GLP-1 in supraphysiological amounts or administration of GLP-1 receptor agonists are capable of inducing insulin secretion ...

Role of glucagon-like peptide-1 receptor agonists in the treatment of ...

Apart from lowering glucose levels, GLP-1RAs also lead to significant weight loss; therefore, they are currently the gold standard in the ...

Incretins (GLP-1 receptor agonists and dual/triple agonists) and the ...

The LEAD studies assessed the role of liraglutide in the management of type 2 diabetes mellitus and obesity. Subsequent analyses of these studies demonstrated ...

Incretin Hormones in Obesity and Related Cardiometabolic Disorders

Research evidence shows that gastrointestinal (GI) tract hormones incretins may play a vital role in the pathogenesis and treatment of obesity and its ...

Utilizing incretin mimetics for the treatment of obesity and overweight

This article focuses on incretin mimetics, glucagon-like peptide 1 receptor agonists that mimic gut hormones known to have an integral role in ...

Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for ...

The discovery of long-acting incretin receptor agonists represents a major stride forward in tackling the dual epidemic of obesity and diabetes.

Review GLP-1 receptor agonists in the treatment of type 2 diabetes

GLP-1 receptor agonists lower body weight by their influence on the central nervous system. •. GLP-1 R reduce cardiovascular events (myocardial infarction, ...

What is the pipeline for future medications for obesity? - Nature

Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management ...